{"id":5963,"date":"2019-09-18T14:35:00","date_gmt":"2019-09-18T09:05:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5963"},"modified":"2025-05-08T11:49:06","modified_gmt":"2025-05-08T06:19:06","slug":"fda-approves-ibsrela-to-reduce-the-global-burden-of-irritable-bowel-syndrome-with-constipation","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/fda-approves-ibsrela-to-reduce-the-global-burden-of-irritable-bowel-syndrome-with-constipation","title":{"rendered":"FDA approves Ibsrela to reduce the global burden of Irritable Bowel Syndrome"},"content":{"rendered":"\n

Recently the U.S. Food and Drug Administration<\/a> has recommended the use of Ibsrela<\/strong> (tenapanor), for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
A 50 mg, twice daily oral pill, Ibsrela<\/strong> is a small molecule that acts locally in the gastrointestinal tract to inhibit the sodium-hydrogen exchanger NHE3. The approval came after the positive results based on data from two phases 3, randomized, double-blind, placebo-controlled trials.<\/p>\n\n\n\n

Irritable Bowel Syndrome<\/a> (IBS), also known as spastic colon, irritable colon, mucous colitis, and spastic colitis, is a long-term digestive system condition, resulting in cramping, abdominal pain, bloating, gas, and diarrhoea or constipation, or both.<\/p>\n\n\n\n

In layman\u2019s terms, it is the\nbelly pain (abdominal pain) associated with constipation.<\/p>\n\n\n\n

According to the National Institute of Health, Irritable bowel syndrome incidence <\/a>is calculated to be around 1 in 5 people, and it usually first develops when a person is between 20 and 30 years of age. Moreover, in the US, as many as 13 million adults suffer from irritable bowel syndrome with constipation. <\/p>\n\n\n\n

Irritable Bowel Syndrome is known to affect twice as many women as\ncompared to men. <\/strong><\/p>\n\n\n\n

Management of Irritable Bowel\nSyndrome consists primarily of providing psychological support and recommending\ndietary measures.<\/p>\n\n\n\n

Although a few FDA-approved\nmedications like Linzess (Ironwood Pharmaceuticals), Trulance (Synergy\nPharmaceuticals), Bentyl (Axcan Scandipharm), Amitiza (Sucampo Pharmaceuticals)\nare available to treat IBS symptoms, several of these drugs have strict\nlimitations on use. Many patients do not find complete symptomatic relief, even\nwhen physicians explore off-label drug options.<\/p>\n\n\n\n

Key players such as Redhill Bio,\nArdelyx Inc. and others are involved in the development of IBS therapies. The\nlaunch of emerging therapies such as BEKINDA<\/strong>\nby Redhill Bio and Tenapanor<\/strong> by Ardelyx\nInc. will significantly impact the Irritable Bowel Syndrome market during the\nforecast period (2019-2028).<\/p>\n\n\n\n

Apart from these therapies, there are other promising IBS candidates as well, which are being developed for the treatment of Irritable Bowel Syndrome. <\/a><\/p>\n\n\n\n

Few of such drug molecules\ninclude Vibegron developed by Urovant Sciences GmbH, Blautix by 4D pharma plc\nand Rifamycin SV-MMX developed by Cosmo Technologies Ltd. However, these molecules\nare currently in early Phase-II stage of development. Hence, it is too soon to\npredict their future during the forecast period (2019-2028).<\/p>\n","protected":false},"excerpt":{"rendered":"

Recently the U.S. Food and Drug Administration has recommended the use of Ibsrela (tenapanor), for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. A 50 mg, twice daily oral pill, Ibsrela is a small molecule that acts locally in the gastrointestinal tract to inhibit the sodium-hydrogen exchanger NHE3. The approval came after […]<\/p>\n","protected":false},"author":1,"featured_media":5969,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[704,3622,17780,17781,6213],"industry":[17225],"therapeutic_areas":[17239],"class_list":["post-5963","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-fda","tag-irritable-bowel-syndrome","tag-irritable-bowel-syndrome-market","tag-irritable-bowel-syndrome-pipeline","tag-irritable-bowel-syndrome-therapy","industry-pharmaceutical","therapeutic_areas-gastroenterology"],"acf":[],"yoast_head":"\nFDA approval to Ibsrela for Irritable Bowel Syndrome | DelveInsight<\/title>\n<meta name=\"description\" content=\"FDA has recommended the use of Ibsrela (tenapanor), for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/fda-approves-ibsrela-to-reduce-the-global-burden-of-irritable-bowel-syndrome-with-constipation\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA approval to Ibsrela for Irritable Bowel Syndrome | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"FDA has recommended the use of Ibsrela (tenapanor), for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/fda-approves-ibsrela-to-reduce-the-global-burden-of-irritable-bowel-syndrome-with-constipation\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-09-18T09:05:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T06:19:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/10142455\/vinita-blog.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA approval to Ibsrela for Irritable Bowel Syndrome | DelveInsight","description":"FDA has recommended the use of Ibsrela (tenapanor), for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/fda-approves-ibsrela-to-reduce-the-global-burden-of-irritable-bowel-syndrome-with-constipation","og_locale":"en_US","og_type":"article","og_title":"FDA approval to Ibsrela for Irritable Bowel Syndrome | DelveInsight","og_description":"FDA has recommended the use of Ibsrela (tenapanor), for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.","og_url":"https:\/\/www.delveinsight.com\/blog\/fda-approves-ibsrela-to-reduce-the-global-burden-of-irritable-bowel-syndrome-with-constipation","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-09-18T09:05:00+00:00","article_modified_time":"2025-05-08T06:19:06+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/10142455\/vinita-blog.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/fda-approves-ibsrela-to-reduce-the-global-burden-of-irritable-bowel-syndrome-with-constipation","url":"https:\/\/www.delveinsight.com\/blog\/fda-approves-ibsrela-to-reduce-the-global-burden-of-irritable-bowel-syndrome-with-constipation","name":"FDA approval to Ibsrela for Irritable Bowel Syndrome | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/fda-approves-ibsrela-to-reduce-the-global-burden-of-irritable-bowel-syndrome-with-constipation#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/fda-approves-ibsrela-to-reduce-the-global-burden-of-irritable-bowel-syndrome-with-constipation#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/10142455\/vinita-blog.png","datePublished":"2019-09-18T09:05:00+00:00","dateModified":"2025-05-08T06:19:06+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"FDA has recommended the use of Ibsrela (tenapanor), for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/fda-approves-ibsrela-to-reduce-the-global-burden-of-irritable-bowel-syndrome-with-constipation"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/fda-approves-ibsrela-to-reduce-the-global-burden-of-irritable-bowel-syndrome-with-constipation#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/10142455\/vinita-blog.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/10142455\/vinita-blog.png","width":772,"height":482,"caption":"Irritable bowel syndrome"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/09\/10142455\/vinita-blog-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Irritable Bowel syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Irritable Bowel Syndrome Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Irritable Bowel Syndrome Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">irritable bowel syndrome therapy<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Irritable Bowel syndrome<\/span>","<span class=\"advgb-post-tax-term\">Irritable Bowel Syndrome Market<\/span>","<span class=\"advgb-post-tax-term\">Irritable Bowel Syndrome Pipeline<\/span>","<span class=\"advgb-post-tax-term\">irritable bowel syndrome therapy<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Sep 18, 2019","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on Sep 18, 2019 2:35 pm","modified":"Updated on May 8, 2025 11:49 am"},"featured_img_caption":"Irritable bowel syndrome","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5963","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5963"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5963\/revisions"}],"predecessor-version":[{"id":31875,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5963\/revisions\/31875"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5969"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5963"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5963"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5963"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5963"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5963"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}